朗生医药(00503.HK)9月25日出售109.22万股司太立股份
格隆汇9月25日丨朗生医药(00503.HK)公布,于2019年9月25日,根据司太立出售授权及第五次股份减持计划,公司以平均每股人民币29.03元(较上海交易所前一个交易日的收盘价折让10%)的价格在市场出售合共109.22万股司太立股份,扣除交易成本及相关税款前的出售所得款项总额约为人民币3171万元。
由于该出售,集团预计能获得约274万美元的净收益,该收益是根据出售净收益与投资司太立的本集团帐面成本的差异计算的。
公司自获得司太立出售授权之日起合共出售了805.01万股司太立股份。在此次出售后,集团仍持有839.49万股司太立股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.